Asset Name: IBI324 (OLN324)
Licensor (Seller): Innovent Biologics (China)
Licensee (Buyer): Ollin Biosciences (US)
.
Asset Modality: Bispecific antibody (BsAb)
Asset Target: VEGF/Ang2
Potential Indication: wet AMD and DME (wet (neovascular) age-related macular degeneration or diabetic macular edema)
Current Stage: Phase I
.
Scope of Authority: Undisclosed.
.
Payment Detail: Undisclosed.
.
Link:
.
Note:
Chinese Name of Innovent Biologics, 信达生物
